We enroll patients in clinical trials as part of the UH Seidman Cancer Center and as the clinical arm of the Case Comprehensive Cancer Center. Through trials, patients receive cutting edge therapies to treat cancer and cancer-related symptoms.
- Pancreas Cancer Trials
The combination of a new mitochondrial inhibitor (CPI-613) and conventional chemotherapy in patients with locally advanced pancreatic cancer (Active, PI Jeff Hardacre)
This trial evaluates the effect of targeting the power generator of the cancer cell, in combination with chemotherapy.
The evaluation of routine use of anti-depressant vs. placebo in preventing depression in patients with localized pancreatic cancer (Pending, PI Jordan Winter)
This trial evaluates routine anti-depressant administration to improve quality of life and prevent depression in patients with pancreatic cancer.
Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma (PI Luke Rothermel)
This trial evaluates the upfront administration of checkpoint inhibitors to see if patients benefit from earlier initiation of immunotherapy.
RO7198457/Pembrolizumab vs Pembrolizumab alone for previously untreated advanced melanoma (subsite PI Luke Rothermel; (Genentech, GENE1619)
This trial evaluates a personalized cancer vaccine made from tumor proteins within a patient’s particular tumor, given concurrently with the standard of care Anti-PD1 checkpoint inhibitor
- Breast Cancer
Alliance trial A221702: ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping (subsite PI Megan Miller)
This trial seeks to better understand lymph drainage and arm swelling after breast surgery.